A prior retrospective study from Van de Wyngaert et al. treated 14 patients with CD30 + R/R PTCL using this regimen however the reported ORR was lower at 29% with a CR rate of 14%.12 The gene discussed is TNFRSF8; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.